New pain pill HRS-6257 enters first human tests
NCT ID NCT07301333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new drug, HRS-6257, in 80 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and measure drug levels in the blood. The study also looks at how food affects the drug and includes a cold pain test to get an early read on pain response, but it is not designed to prove the drug works for pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-6257
What this could lead to
If successful, this could point toward a new oral pain medication.
What could go wrong
This is a very early Phase 1 study in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it actually relieves pain. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Third Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410013, China
Contact
Contact